Importantly, employing a Nrp-1 inhibitor alongside a 4-1BB agonist in humanized HCC models demonstrates favorable outcomes and safety, augmenting the anti-tumor effects of PD-1 blockade (6). The gene discussed is NRP1; the disease is neoplasm.